Piper Sandler raised the firm’s price target on Bristol Myers (BMY) to $66 from $65 and keeps an Overweight rating on the shares. In the wake of Bristol’s Q1 print, the firm is updating its model, with the bulk of the upward revisions to its sales estimates coming from the company’s legacy business. Regarding the growth portfolio, beyond Cobenfy, Piper is keeping a particularly watchful eye on execution surrounding Sotyktu and Camzyos.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers Chief Medical Officer buys $202K in common stock
- Bristol Myers price target lowered to $47 from $56 at HSBC
- Bristol Myers price target lowered to $52 from $54 at UBS
- Bristol Myers price target raised to $56 from $54 at BofA
- Bristol Myers price target lowered to $53 from $62 at Wells Fargo